ABSTRACT
Hyperamylasemia in patients with lung cancer is relatively rare, occurring in 1-3% of all cases of the disease. The pathogenesis of hyperamylasemia in solid cancers is not clear. In Korea, no cases of hyperamylasemia have been reported in patients with adenocarcinoma of the lung. Instead, the lung cancers in patients with hyperamylasemia have in most cases been adenocarcinomas. We report a case of a 64-year-old woman with hyperamylasemia that was suspected to have been induced by mucinous adenocarcinoma of the lung. The patient's amylase isoenzyme pattern was of the salivary type. Systemic chemotherapy normalized her serum amylase levels and produced a partial response in her lung cancer.
Subject(s)
Female , Humans , Middle Aged , Adenocarcinoma , Adenocarcinoma, Mucinous , Amylases , Hyperamylasemia , Korea , Lung , Lung NeoplasmsABSTRACT
Hyperamylasemia in patients with lung cancer is relatively rare, occurring in 1-3% of all cases of the disease. The pathogenesis of hyperamylasemia in solid cancers is not clear. In Korea, no cases of hyperamylasemia have been reported in patients with adenocarcinoma of the lung. Instead, the lung cancers in patients with hyperamylasemia have in most cases been adenocarcinomas. We report a case of a 64-year-old woman with hyperamylasemia that was suspected to have been induced by mucinous adenocarcinoma of the lung. The patient's amylase isoenzyme pattern was of the salivary type. Systemic chemotherapy normalized her serum amylase levels and produced a partial response in her lung cancer.
Subject(s)
Female , Humans , Middle Aged , Adenocarcinoma , Adenocarcinoma, Mucinous , Amylases , Hyperamylasemia , Korea , Lung , Lung NeoplasmsABSTRACT
Hematologic malignancies and lymphoproliferative disorders have been reported after using tumor necrosis factor-alpha inhibitor in patients suffering from spondyloarthropathy. Previously reported cases were treated by using infliximab and etanercept. Usually, it takes approximately several months for leukemia or lymphoproliferative disorders to occur after the application of those agents. However, we report a case of acute myeloid leukemia that developed after short term usage of adalimumab in a patient suffering from psoriatic arthritis.
Subject(s)
Humans , Antibodies, Monoclonal , Antibodies, Monoclonal, Humanized , Arthritis, Psoriatic , Hematologic Neoplasms , Immunoglobulin G , Leukemia , Leukemia, Myeloid, Acute , Lymphoproliferative Disorders , Receptors, Tumor Necrosis Factor , Spondylarthropathies , Stress, Psychological , Tumor Necrosis Factor-alpha , Adalimumab , Infliximab , EtanerceptABSTRACT
The genus Alternaria contains several species of melanized hypomycetes that cause opportunistic human infections. The most frequent clinical manifestations of alternariosis are cutaneous and subcutaneous infections, followed by oculomycosis, invasive and non-invasive rhinosinusitis, and onychomycosis. So far, only 17 cases of rhinosinusitis caused by Alternaria species have been reported since 1977. Although several domestic cases of cutaneous alternariosis have been reported, there is no report of Alternaria rhinosinusitis in Korea. The majority of Alternaria rhinosinusitis involves immunocompromised patients. We report the first case of alternariosis in a patient with neutropenia and myelodysplastic syndrome that was treated with endoscopic debridement and a conventional antifungal agent.
Subject(s)
Humans , Alternaria , Alternariosis , Debridement , Eye Infections, Fungal , Immunocompromised Host , Korea , Myelodysplastic Syndromes , Neutropenia , Onychomycosis , SinusitisABSTRACT
Acute promyelocytic leukemia (APL), which is usually defined by the morphological features of the leukemic cells, is characterized by the t(15;17) (q22;q21) chromosomal translocation and disseminated intravascular coagulation. This specific translocation results in a new fusion transcript between the promyelocytic leukemia (PML) gene and the retinoic acid receptor-alpha (RARalpha) gene. Although the presence of this fusion gene can predict a favorable clinical response to all-trans-retinoic-acid (ATRA) treatment, APL with chromosomal translocations other than t(15;17) (q22;q21) is extremely rare and is associated with a poor prognosis. We experienced a case of APL with de novo t(11;19).